趙子(zǐ)賢先生先後在(zài)Pharmacia、Amgen、AstraZeneca等多家世界500強制藥企業和(hé / huò)大(dà)、中型生物技術公司中成功創建和(hé / huò)有效領導了(le／liǎo)全球性和(hé / huò)區域性藥物安全部門、藥物安全監測團隊和(hé / huò)藥物流行病學團隊，并有效地(dì / de)管理了(le／liǎo)藥物臨床開發和(hé / huò)市場協作夥伴的(de)藥物安全工作以(yǐ)及藥物安全供應商管理。

Medical PhD, epidemiologist, with 25 years of experience in global innovative drugs development as senior manager, has proven multi-professional work, scientific research and management capabilities, including clinical research and development of innovative drugs, pharmacovigilance and Safety, pharmacoepidemiology, observational studies, post-marketing safety research and monitoring, post-marketing real-world evidence establishment, drug safety risk assessment management and risk minimization strategies and measures, disease management, establishment of enterprise drug safety standards and procedures and Improvement, as well as research on Pharmacoeconomics and clinical endpoint indicators.

Dr.Zhao has successfully established and effectively led the global and regional drug safety departments, drug safety monitoring teams and drug epidemiology teams in many of the world's top 500 pharmaceutical companies and large and medium-sized biotechnology companies such as Pharmacia, Amgen, and AstraZeneca , and effectively managed the drug safety work of drug clinical development and market collaboration partners, as well as drug safety supplier management.

Mr. Zhao has profound knowledge of laws, regulations and guidelines on drug development and pharmacovigilance, and has long and successful communication with FDA,EMA,NMPA,PMDA and other regulatory agencies.